JW Pharmaceutical, which has been hitting new highs in share prices for 52 consecutive weeks, met the market’s expectations by posting a record performance in the second quarter.On Wednesday, JW Pharm released preliminary operating results for the second quarter in a public filing.On a standalone ba
Prestige Biopharma said on Friday that it signed a memorandum of understanding (MOU) with Imagion Biosystems, a U.S. imaging diagnostics company, to develop an early diagnosis platform for pancreatic cancer. Under the partnership, Prestige Biopharma will provide pancreatic adenocarcinoma up-regulate
MSD Korea has recently applied for expanding reimbursement for Keytruda (pembrolizumab) to cover all its 13 cancer indications with high unmet needs.Among indications newly requested for coverage are triple-negative breast, head and neck, and esophageal cancers, which are aggressive enough to threat
Just a few weeks after the official launch of Samsung Bioepis and Organon’s Humira (ingredient: adilumab) biosimilar, Hadlima, in the U.S. market, it is quickly gaining traction, after being added to two large U.S. insurers.This marks the fourth U.S. insurer to register the drug. Previously, Prime T
Children's cold medicines suspended due to quality control issues are back on the market after improvements.The Ministry of Food and Drug Safety said Thursday that it had lifted the suspension of manufacturing and sales of Dong-A Pharmaceutical's Champ Syrup and Daewon Pharmaceutical's Coldaewon Kid
Hugel said it recorded the largest second quarterly earnings in its history, thanks to strong sales from its botulinum toxin, fillers, and cosmetic lineup.The company's sales and operating profit for the second quarter was 81.6 billion won ($61.9 million) and 21.4 billion won, both up 28 percent com
BL Science, a subsidiary of BL Pharmtech, said on Thursday that it signed an agreement with Kumoh National Institute of Technology, a local university, to jointly develop a cancer diagnosis solution utilizing artificial intelligence (AI) in tissue and cellular pathology diagnosis.BL Science is a dia
For Korean pharmaceutical products to compete in overseas markets, the nation must urgently improve its drug pricing system by, for instance, assigning appropriate values to new drugs, experts said.They added that the industry must also raise the self-sufficiency rate of homegrown active pharmaceuti
Ildong Pharmaceutical said on Wednesday that it will separate its research and division (R&D) department and establish a subsidiary to boost profitability and R&D.Ildong Pharmaceutical will maintain a 100 percent stake in the new company as the parent company. The tentative name of the corporation i
Korea's healthcare industry is doubling efforts to support participants of the 25th World Scout Jamboree, although its organizers were heavily criticized for disorganization and unpreparedness.Most recently, Daewoong Co. said that it has fully opened its human resource development (HRD) training cen
EONE-Diagnomics Genome Center (EDGC) said on Thursday that it formed a task force for the Cancer Moonshot project and is in discussions with the CancerX team about joining as a member with its companion diagnostic (CDx) liquid biopsy, ONCOCATCH.EONE-Diagnomics Genome Center is a joint venture betwee
Palatin Technologies, a U.S. pharmaceutical company, said that Kwangdong Pharmaceutical, its Korean partner, has nearly completed a phase 3 clinical trial in Korea for Vyleesi (ingredient: bremelanotide), a hypoactive sexual desire disorder (HSDD) treatment for women. Kwangdong licensed in Vyleesi i
Huons recorded its best performance ever in the second quarter this year.The company released its second-quarter performance in a public filing Tuesday.On a consolidated basis, Huons reported second-quarter revenue of 140.7 billion won ($106.5 million), operating income of 17.9 billion won, and net
Hanmi Pharm’s nonalcoholic steatohepatitis (NASH) drug candidate, efinopegdutide (HM12525A), licensed out to MSD, is increasingly likely to emerge as a best-in-class treatment thanks to organic collaboration between the two partners.At a workshop co-organized by MSD Korea and the Korean Health Indus
SK bioscience said on Wednesday that it made an equity investment in Novavax, a U.S. vaccine maker, paying $85 million (approximately 112 billion won) to secure 6.5 million shares of common stock through a private placement, equating to a 7 percent stake in the company.Due to weakening demand for it
Korea Biomedical Review is publishing a series of articles to analyze the top 10 Korean pharmaceutical and biopharma companies with the largest market capitalizations listed on the main bourse, Kospi, and the tech-heavy Kosdaq. The series aims to reflect key industrial issues and the flow of the cap
Daewon Pharmaceutical has taken the first step toward conducting clinical trials to develop a semaglutide-based obesity treatment as a patch.Daewon Pharm and Raphas said Tuesday they had completed the investigational new drug application for a phase 1 clinical trial of DW-1022, a microneedle patch o
Genome&Company, a Korean microbiome therapeutics company, said on Tuesday that it signed a memorandum of understanding (MOU) with HEM Pharma, another Korean firm specializing in microbiome therapeutics, to jointly advance microbiome drug development.As both companies are developing new drugs based o
Japan's Daiichi Sankyo, a fast-growing player in the HER2 breast cancer space with its antibody-drug conjugate (ADC) Enhertu, is yet again receiving attention after succeeding in developing a Covid-19 mRNA vaccine.According to Daiichi Sankyo, the Japanese drug ministry approved Daichirona, its Covid
Boryung, formerly Boryung Pharmaceutical, said Monday that its new anticancer drug, BR101801, has been designated as a developmental orphan drug by the Korean Ministry of Food and Drug Safety.The designation was made to address the unmet medical needs of peripheral T-cell lymphoma (PTCL), a rare can